(Q35954388)

English

Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? (English)

1 reference

Europe PubMed Central

11 August 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

author name string

Ciara Barrett

1

1 reference

Europe PubMed Central

11 August 2017

Hilary Magee

2

1 reference

Europe PubMed Central

11 August 2017

Denise O'Toole

3

1 reference

Europe PubMed Central

11 August 2017

Sinead Daly

4

1 reference

Europe PubMed Central

11 August 2017

Michael Jeffers

5

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

5 July 2006

1 reference

Europe PubMed Central

11 August 2017

Journal of Clinical Pathology

1 reference

Europe PubMed Central

11 August 2017

60

1 reference

Europe PubMed Central

11 August 2017

6

1 reference

Europe PubMed Central

11 August 2017

690-693

1 reference

Europe PubMed Central

11 August 2017

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Best Practice No 176: Updated recommendations for HER2 testing in the UK

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

2 October 2017

High-quality HER-2 testing: setting a standard for oncologic biomarker assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

24 September 2018

HER-2 testing in breast cancer using parallel tissue-based methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

24 September 2018

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

24 September 2018

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

24 September 2018

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

24 September 2018

C-erbB-2 overexpression and survival in early onset breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1955078

24 September 2018

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From the molecule to the clinic--inhibiting HER2 to treat breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16822876

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/JCP.2006.039602

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35954388&oldid=1522084728"